Duo Oncology
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Duo Oncology - backed by BeOne - is a cancer medicine company developing next-generation chemotherapy for solid tumors. Its lead program, DUO-207, consolidates commonly co-administered cytotoxic agents into a single, tumor-targeted prodrug designed to improve intratumoral exposure while reducing systemic toxicity. The program is supported by completed IND-enabling studies, orphan drug designations, and strong preclinical benchmarks versus standard of care. Duo is advancing toward first-in-human studies with a capital-efficient clinical strategy focused on rapid clinical validation and strategic partnering, supported by both strategic pharmaceutical investment and non-dilutive funding.
Company HQ City:
Pittsburgh
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
DUO-207 prodrug nanomedicine polymer conjugate gemcitabine + paclitaxel.
CEO
Sam Rothstein
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Q4 2026
What is your next catalyst (value inflection) update?
Phase 1b FPI
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}